Trevi Therapeutics Inc (TRVI)

$3.23

+0.06

(+1.89%)▲

Live

Performance

  • $3.12
    $3.39
    $3.23
    downward going graph

    3.41%

    Downside

    Day's Volatility :7.96%

    Upside

    4.72%

    downward going graph
  • $0.97
    $4.00
    $3.23
    downward going graph

    69.97%

    Downside

    52 Weeks Volatility :75.75%

    Upside

    19.25%

    downward going graph

Returns

PeriodTrevi Therapeutics IncIndex (Russel 2000)
3 Months
14.03%
0.0%
6 Months
103.21%
0.0%
1 Year
37.23%
0.0%
3 Years
34.32%
-20.2%

Highlights

Market Capitalization
209.2M
Book Value
$1.05
Earnings Per Share (EPS)
-0.34
Wall Street Target Price
7.33
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-24.56%
Return On Equity TTM
-38.57%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-38.1M
Diluted Eps TTM
-0.34
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.43
EPS Estimate Next Year
-0.47
EPS Estimate Current Quarter
-0.09
EPS Estimate Next Quarter
-0.1

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Trevi Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 126.93%

Current $3.23
Target $7.33

Technicals Summary

Sell

Neutral

Buy

Trevi Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Trevi Therapeutics Inc
Trevi Therapeutics Inc
19.62%
103.21%
37.23%
34.32%
34.32%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Trevi Therapeutics Inc
Trevi Therapeutics Inc
NA
NA
NA
-0.43
-0.39
-0.25
NA
1.05
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Trevi Therapeutics Inc
Trevi Therapeutics Inc
Buy
$209.2M
34.32%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Trevi Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 24.4%

Institutional Holdings

  • NEA Management Company, LLC

    16.14%

  • Rubric Capital Management LP

    7.90%

  • Viking Global Investors LP

    6.25%

  • VR Adviser, LLC

    4.86%

  • Opaleye Management Inc

    3.76%

  • BlackRock Inc

    3.37%

Company Information

trevi therapeutics, inc. is a late-stage biopharmaceutical company focused on developing nalbuphine® er for chronic pruritic conditions. pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. the company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions (excoriative/ulcerative papules and nodules) on the skin. there are no approved therapies in the us or eu for this condition. nalbuphine® er is an oral extended release synthetic opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch. because of nalbuphine® er’s unique dual mechanism of action, which has shown efficacy in addressing pruritus in human clinical trials, the company believes nalbuphine® er can

Organization
Trevi Therapeutics Inc
Employees
25
CEO
Ms. Jennifer L. Good
Industry
Pharmaceuticals: Major

Discover More

FAQs